title: Phase I/II trial of biweekly paclitaxel and cisplatin in the treatment of metastatic breast cancer.
abstract: OBJECTIVE
  To determine the maximum-tolerated dose of escalating doses of paclitaxel (Taxol; Bristol-Myers Squibb, Princeton, NJ) administered biweekly with a fixed dose of cisplatin, to assess the toxicity, and to evaluate the activity of this combination in a phase I/II trial in metastatic breast cancer.
  
  
  METHODS
  Twenty-nine women with metastatic breast cancer were enrolled; 27 were assessable for response and 29 for toxicity. All but two of the women had received prior adjuvant chemotherapy, with 23 receiving anthracyclines and six previous cisplatin.
  
  
  RESULTS
  The initial starting dose of paclitxel 90 mg/m2 and cisplatin 60 mg/m2 became the phase II dose due to dose-limiting neutropenia. Responses were seen in 85% of assessable patients, with three patients (11%) achieving a complete response (CR) and 20 patients (14%) a partial response (PR), for an overall response rate of 85% (95% confidence interval [CI], 66% to 96%). The time to disease progression for patients who achieved a CR was 110 to 200 days, and for those with a PR, it was 96 to 377+ days, with a median time to progression of 7.1 months and a median response duration of 7.9 months. Sites of CR were skin, soft tissue, and lung, and all occurred in women with previous exposure to anthracyclines. Septic events were rare, with two grade 3 infections (7%), only one of which required hospital admission. There were no grade 4 nonhematologic toxicity and minimal grade 3 toxicity. A total of 251 chemotherapy cycles were given -- 16 with paclitaxel alone in five patients. Forty-five percent of patients required dose reductions, while 52% had delays due to neutropenia.
  
  
  CONCLUSIONS
  Biweekly paclitaxel and cisplatin is an active combination in the treatment of metastatic breast cancer, including for patients with previous exposure to anthracyclines.
authors.affiliation: British Columbia Cancer Agency, Vancouver, Canada.
authors.forename: K A
authors.initials: KA
authors.lastname: Gelmon
authors.forename: S E
authors.initials: SE
authors.lastname: O'Reilly
authors.forename: A W
authors.initials: AW
authors.lastname: Tolcher
authors.forename: C
authors.initials: C
authors.lastname: Campbell
authors.forename: C
authors.initials: C
authors.lastname: Bryce
authors.forename: J
authors.initials: J
authors.lastname: Ragaz
authors.forename: C
authors.initials: C
authors.lastname: Coppin
authors.forename: I H
authors.initials: IH
authors.lastname: Plenderleith
authors.forename: D
authors.initials: D
authors.lastname: Ayers
authors.forename: B
authors.initials: B
authors.lastname: McDermott
authors.forename: L
authors.initials: L
authors.lastname: Nakashima
authors.forename: D
authors.initials: D
authors.lastname: Healey
authors.forename: N
authors.initials: N
authors.lastname: Onetto
mesh_terms: D000328:Adult; D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D002945:Cisplatin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel; D002945:Cisplatin